Clinical trials: Orthomyxoviridae Infections
Healthy
Non-Inferiority Study Comparing the Subunit Vaccines Influvac and Agrippal in China
In the study Influvac will be compared to Agrippal, another subunit influenza vaccine that is already on the market in China. The main objective of the study is to show that both vaccines are comparable with regard to efficacy.
- Trial name
- NCT00325260
- Testing
- Influvac; subunit influenza vaccine
- Where
- China
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Solvay Pharmaceuticals
Influenza
Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Elderly Subjects
To evaluate the antibody response to each influenza vaccine antigen when administering a single dose to subjects aged 65 years and over
- Trial name
- NCT00329927
- Testing
- Surface Antigen, Inactivated, (Adjuvanted with MF59C.1), form. 2006-07
- Where
- 2 sites in Italy
- Volunteers
- 60 people
- Sponsor
- Novartis
Influenza, Human
Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults
This is a safety and Immunogenicity first-in-human dose-ranging study of self-amplifying RNA Seasonal Influenza Vaccine (ARCT-2138) in adults.
- Trial name
- NCT06125691
- Testing
- ARCT-2138, Licensed Quadrivalent Vaccine for younger adults, Licensed Quadrivalent Vaccine for older adults
- Where
- 2 sites in Australia
- Volunteers
- 139 people, healthy volunteers welcome
- Sponsor
- Arcturus Therapeutics, Inc.
Influenza, Human
Intramuscular CodaVax-H1N1 in Healthy Adults
This study is a Phase 1, 2-part, randomised, double-blind, controlled, clinical trial to evaluate the safety and immune response of CodaVax-H1N1 in healthy adults aged 18 to 49 years.
- Trial name
- NCT05223179
- Testing
- CODA-VAX H1N1, Flucelvax Quad, Saline
- Where
- Australia
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Codagenix, Inc
Influenza
Safety and Immunogenicity of the 2015-2016 Formulation of Fluzone® Quadrivalent (Influenza Vaccine) Among Healthy Children
The study will evaluate the safety and immunogenicity of the 2015-2016 formulation of Fluzone Quadrivalent vaccine, administered in a 1- or 2-dose schedule, in accordance with the Advisory Committee on Immunization Practices…
- Trial name
- NCT02539108
- Testing
- Fluzone® Quadrivalent Influenza Vaccine, No Preservative
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Pneumococcal Polysaccharide Vaccine, Influenza Vaccines
Preoperative Pneumococcal and Influenza Vaccination to Prevent Postoperative Pulmonary Infection in Patients Undergoing Lung Resection for Pulmonary Nodules or Lung Cancer
Postoperative pneumonia (POP) affects 4%-24% of lung cancer surgery patients, increasing mortality, stay, costs and worsening prognosis, especially in older patients.
- Conditions
- Pneumococcal Polysaccharide Vaccine, Influenza Vaccines, Preoperative, Lung Resection Surgery
- Trial name
- NCT07885540
- Testing
- 23-valent pneumococcal polysaccharide vaccine, Quadrivalent split-virion influenza vaccine
- Volunteers
- 1,278 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Influenza, Behavior and Behavior Mechanisms
Nationwide Utilization of Danish Government Electronic Letter System for Confirming the Effectiveness of Behavioral Nudges in Increasing InFLUenza Vaccine Uptake Among Adults With Chronic Disease
In randomized clinical trials and observational studies, influenza vaccination has been shown to be effective in reducing influenza-related illness, hospitalizations, cardiovascular events, and mortality in select populations.
- Trial name
- NCT06600490
- Testing
- Behavioral Economic Principles
- Where
- Denmark
- Volunteers
- 308,978 people
- Sponsor
- Tor Biering-Sørensen
Influenza
Live Attenuated Influenza Vaccine (LAIV) Versus Trivalent Inactivated Influenza Vaccine in Healthy Adults 18-49 Years
This randomized, open-label, single-site study at Saint Louis University will enroll approximately 40 subjects who are healthy, 18 to 49 years old.
- Trial name
- NCT03101462
- Testing
- Inactivated Influenza Vaccine, Live Attenuated Influenza Vaccine
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- St. Louis University
Influenza, Acute Respiratory Infection
Effectiveness Assessment of Vaccinating Schoolchildren Against Influenza
Vaccinating schoolchildren against influenza would prevent the disease among non-vaccinated household members.
- Trial name
- Xo_Gripe (NCT01693380)
- Testing
- Influenza vaccine, Control vaccine
- Where
- Brazil
- Volunteers
- 1,742 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
H1N1 Influenza Virus
Analysis of the Results From Influenza Rapid Test A Positive and H1N1 Real Time RT-PCR
The first outbreak of a new H1N1 influenza pandemic originated in the North America in April 2009. As of July 1, 2009, a total of 77,201 cases were accumulated in 103 countries around the world and the mortality rate of was about…
- Trial name
- NCT01277380
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Taipei Medical University WanFang Hospital
Influenza Immunization
Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years
The purpose of this study was to demonstrate the non-inferior HAI immune response of quadrivalent recombinant influenza vaccine (RIV4) vs licensed Egg-Based Quadrivalent Influenza Vaccine (IIV4) for the 4 strains based on the…
- Trial name
- NCT05513391
- Testing
- Recombinant influenza vaccine (RIV4), Quadrivalent influenza vaccine (IIV4)
- Where
- 31 sites in United States, Poland and 1 more
- Volunteers
- 366 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Study to Evaluate the Effectiveness of FluMist Vaccination in a School-Based Intervention Program
To measure the effectiveness of influenza vaccination in school children by comparing, between target(i.e., children are offered FluMist) and control (i.e., children are not offered FluMist) school families.
- Trial name
- NCT00192218
- Testing
- FluMist
- Where
- 2 sites in United States
- Volunteers
- 3,022 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza
A Study to Evaluate the Immune Response and Safety of a Seasonal Virus-Like Particle Influenza Vaccine in Healthy Young Adults
The purpose of this study is to determine the immune response of three dose levels of the Novavax Quadrivalent vaccine in healthy young adults (18-64). The study is broken down into 5 treatment groups.
- Trial name
- NCT01561768
- Testing
- Novavax Quadrivalent vaccine, Novavax Trivalent vaccine, cTIV
- Where
- 4 sites in Australia
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Novavax
Influenza
FLU-VACS Comparative Study in Adults
The purpose of this study is to compare 2 licensed flu vaccines to each other and to placebo (inactive substance). The study will be conducted among healthy adult participants aged 18-49 years and is expected to last 3 years.
- Trial name
- NCT00133523
- Testing
- Cold-adapted live attenuated influenza virus vaccine, trivalent, Trivalent inactivated influenza vaccine
- Where
- 6 sites in United States
- Volunteers
- 2,349 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Human, COVID-19
This Study Intends to Describe the Characteristics of Patients Given the Pfizer-BioNTech Bivalent mRNA COVID-19 Vaccine and Any Commercially Available Influenza Vaccines at the Same Time Versus at Different Times.
This study intends to describe the characteristics of patients given the Pfizer-BioNTech bivalent mRNA COVID-19 vaccine and any commercially available influenza vaccines at the same time versus at different times.
- Trial name
- NCT05858450
- Testing
- Comirnaty, Quadrivalent Influenza Vaccine
- Where
- United States
- Volunteers
- 3,442,996 people
- Sponsor
- Pfizer
Influenza
Immunogenicity and Safety Study of a GSK Influenza Vaccine Candidate in Adults.
The purpose of this study is to evaluate the safety and immunogenicity of GSK influenza vaccine candidate compared to a licensed trivalent influenza vaccine in adults.
- Trial name
- NCT00714285
- Testing
- GSK Biologicals' quadrivalent influenza vaccine, GSK Biologicals' trivalent influenza vaccine
- Where
- Czechia
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza Vaccination
Family Physician Nudges for Influenza Vaccination Among Older Adults
The goal of this clinical trial is to learn if a family-physician nudge intervention works to improve influenza vaccination among adults aged 65 years and older in China.
- Trial name
- NCT07864597
- Testing
- Family Physician Influenza Vaccination Nudge
- Volunteers
- 3,060 people, healthy volunteers welcome
- Sponsor
- Fudan University
Influenza
A Trial of Oseltamivir in High-Risk Patients Presenting to the Emergency Department With Influenza
A multi-centre, randomized, placebo controlled, trial. Participants will be patients either ≥65 years or with one or more high risk conditions presenting to one of four academic emergency departments in Edmonton or Calgary with…
- Trial name
- NCT02561169
- Testing
- Oseltamivir
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- McMaster University
Influenza, Vaccine Hesitancy
Precision Vaccine Promotion in Underserved Populations
Previous studies have shown that low-cost, behavioral nudges through texting can increase influenza vaccination uptake compared to usual care.
- Trial name
- NCT05537441
- Testing
- Text messaging
- Where
- United States
- Volunteers
- 228,831 people
- Sponsor
- University of Southern California
Influenza in Humans
A Drug-Drug Interaction Study to Evaluate the Effect of AL-794 on the Pharmacokinetics of Oseltamivir and JNJ-63623872
This open-label, four group, fixed-sequence study will evaluate the safety and pharmacokinetic interaction of AL-794 on oseltamivir, JNJ-63623872 (formerly VX-787) and probes for P-glycoprotein, CYP3A and OATP1B1 in healthy…
- Trial name
- NCT02888327
- Testing
- AL-794, Oseltamivir, Digoxin
- Where
- United Kingdom
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Alios Biopharma Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.